AI-NATIVE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY

Advancing regenerative medicine through AI.

Cell Technologies is a clinical-stage AI-native pharmaceutical company. Our proprietary platforms — Oracle and Delfi — drive every stage of cell therapy and biologics development, from candidate selection through clinical decision-making. Our underlying stem cell technology is FDA and Health Canada approved.

FDA + Health Canada approved technology

6 patents + peer-reviewed publications

WHO WE ARE

The future of pain medicine — and beyond.

Cell Technologies is an AI-native biopharmaceutical company. Our proprietary platforms — Oracle and Delfi — drive every stage of cell therapy and biologics development, systematically de-risking the decisions that determine whether new medicines reach patients. Our lead programs treat osteoarthritis and degenerative disc disease; our pipeline extends into neurodegeneration.

Clinical-stage programs in regenerative cell therapy

Proprietary AI platforms — Oracle and Delfi

Patents protecting core technology

10+

Years of clinical and translational research

EXPLORE

What we do

OUR TECHNOLOGY

AI platforms driving cell therapy and biologics

Oracle and Delfi — our proprietary AI platforms — orchestrate every high-risk decision in pharmaceutical R&D. They drive the development of our autologous ChondroStem™ and allogeneic stem cell modalities to market.

Explore the science

PIPELINE

Two clinical programs, one in preclinical development

Lead asset in Phase 3 for knee osteoarthritis, Phase 2 program in degenerative disc disease, and an emerging preclinical program in Parkinson's disease.

View pipeline

INVESTORS

Discover the opportunity

Clinical-stage biopharma at the intersection of regenerative medicine and AI — addressing chronic diseases that affect hundreds of millions globally.

Investor information

AI-NATIVE DRUG DEVELOPMENT

Two proprietary AI platforms — driving the process end to end.

Oracle is our cell therapy operating system — taking any disease as input and producing the optimal stem cell type, QC release framework, and bioreactor blueprint in seconds rather than the months required by traditional methods.

Delfi is our pharmaceutical R&D decision engine — covering candidate identification, clinical trial operations, and full go/no-go decision support for biologics and small molecules.

Together, Oracle and Delfi systematize the high-risk decisions — toxicity prediction, manufacturing at scale, patient selection, trial design, regulatory strategy — that determine whether new medicines reach patients.

Stem cell therapy that targets the cause, not just the symptoms.

Osteoarthritis and degenerative disc disease together affect more than 600 million people worldwide. Current standard of care — NSAIDs, steroids, joint replacement — manages symptoms but doesn't address the underlying tissue degeneration.

Our autologous ChondroStem™ and allogeneic modalities — advanced through Oracle's manufacturing intelligence — deliver live, GMP-grade stem cells engineered to regenerate damaged cartilage and disc tissue. Published clinical data demonstrate significant, sustained reductions in pain and improvements in function.

Learn about our technology →